Guided Therapeutics SG&A Expenses 2010-2024 | GTHP
Guided Therapeutics sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
| Guided Therapeutics Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024 | $2 |
| 2023 | $3 |
| 2022 | $3 |
| 2021 | $2 |
| 2020 | $1 |
| 2019 | $1 |
| 2018 | $1 |
| 2017 | $3 |
| 2016 | $3 |
| 2015 | $5 |
| 2014 | $6 |
| 2013 | $4 |
| 2012 | $4 |
| 2011 | $4 |
| 2010 | $3 |
| 2009 | $2 |
| Guided Therapeutics Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024-12-31 | $0 |
| 2024-09-30 | $0 |
| 2024-06-30 | $0 |
| 2024-03-31 | $0 |
| 2023-12-31 | $0 |
| 2023-09-30 | $1 |
| 2023-06-30 | $1 |
| 2023-03-31 | $1 |
| 2022-12-31 | $1 |
| 2022-09-30 | $1 |
| 2022-06-30 | $1 |
| 2022-03-31 | $0 |
| 2021-12-31 | $1 |
| 2021-09-30 | $0 |
| 2021-06-30 | $1 |
| 2021-03-31 | $1 |
| 2020-12-31 | $0 |
| 2020-09-30 | $0 |
| 2020-06-30 | $0 |
| 2020-03-31 | $0 |
| 2019-12-31 | $0 |
| 2019-09-30 | $0 |
| 2019-06-30 | $0 |
| 2019-03-31 | $0 |
| 2018-12-31 | $0 |
| 2018-09-30 | $0 |
| 2018-06-30 | $0 |
| 2018-03-31 | $0 |
| 2017-12-31 | $0 |
| 2017-09-30 | $1 |
| 2017-06-30 | $0 |
| 2017-03-31 | $0 |
| 2016-12-31 | $1 |
| 2016-09-30 | $1 |
| 2016-06-30 | $1 |
| 2016-03-31 | $1 |
| 2015-12-31 | $1 |
| 2015-09-30 | $1 |
| 2015-06-30 | $1 |
| 2015-03-31 | $1 |
| 2014-12-31 | $2 |
| 2014-09-30 | $2 |
| 2014-06-30 | $1 |
| 2014-03-31 | $1 |
| 2013-12-31 | $1 |
| 2013-09-30 | $1 |
| 2013-06-30 | $1 |
| 2013-03-31 | $1 |
| 2012-12-31 | $1 |
| 2012-09-30 | $1 |
| 2012-06-30 | $1 |
| 2012-03-31 | $1 |
| 2011-12-31 | $2 |
| 2011-09-30 | $1 |
| 2011-06-30 | $1 |
| 2011-03-31 | $1 |
| 2010-12-31 | $1 |
| 2010-09-30 | $1 |
| 2010-06-30 | $1 |
| 2010-03-31 | $1 |
| 2009-12-31 | $1 |
| 2009-09-30 | $0 |
| 2009-06-30 | $0 |
| 2009-03-31 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.008B | $0.000B |
| GUIDED THERAPEUTICS, Inc. is developing a rapid and painless test for the early detection of disease that leads to cervical cancer. The technology is designed to quickly eliminate false positive Pap and HPV results and discover cervical disease missed by existing tests. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are available immediately. GT also owns technology for measuring substances in interstitial fluid, a secondary circulatory system in the body that surrounds the cells. | |||